← Innate Pharma SA
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $44.0m |
$94.0m
+113.37%
|
$85.8m
-8.66%
|
$70.5m
-17.90%
|
$24.7m
-64.94%
|
$57.7m
+133.47%
|
$61.6m
+6.88%
|
$20.1m
-67.36%
|
$9.0m
-55.18%
|
$2.8m
-69.10%
|
|
| Revenue from collaboration and licensing agreements | $32.6m | $79.9m | $69.0m | $56.2m | $12.1m | $49.6m | $51.9m | $12.6m | $2.8m | — | |
| Net Interest Income | — | — | — | — | — | $258k |
$2.5m
+883.33%
|
$1.9m
-26.25%
|
$878k
-53.07%
|
$878k
0.00%
|
|
| Research and development | $67.0m | $69.6m | $78.8m | $58.6m | $47.0m | $51.7m | $56.0m | $52.0m | $43.6m | $43.6m | |
| General and administrative | — | $18.1m | $25.8m | $31.2m | $25.5m | $22.4m | $18.3m | $19.7m | $19.4m | $11.0m | |
| General and administrative expenses | — | — | ($21.0m) | ($19.0m) | ($25.5m) | ($22.4m) | ($18.3m) | ($19.7m) | ($19.4m) | $11.0m | |
| General And Administrative Expense | — | — | — | — | — | $14.5m | $11.7m | $11.9m | $11.0m | $11.0m | |
| Operating expenses: | |||||||||||
| Other Operating Expenses | — | — | — | — | — | ($131k) | ($3.2m) | $284k | $1.6m | — | |
| Total operating expenses | ($84.0m) | ($87.7m) | ($104.6m) | ($133.4m) | ($72.5m) | ($115.1m) | ($74.3m) | ($71.7m) | ($63.0m) | $56.2m | |
| Other Operating Income Expense | ($40.0m) | ($1.5m) | ($1.7m) | ($1.8m) | ($2.2m) | ($795k) | ($872k) | ($1.9m) | ($2.0m) | — | |
| Interest Expense | — | $102k | $204k | $341k | $312k | $288k | $640k | $566k | $440k | $440k | |
| Interest Income | — | — | — | — | — | $546k | $3.2m | $2.4m | $1.3m | $1.3m | |
| Net Non Operating Interest Income Expense | — | — | — | — | — | $258k | $2.5m | $1.9m | $878k | $878k | |
| Gain On Sale Of Security | — | — | — | — | — | ($805k) | $2.6m | $232k | $4.0m | $4.0m | |
| Other Income | — | — | — | $0 | $0 | $59k | $11k | $11k | $13k | — | |
| Other Income Expense | — | — | — | — | — | ($41.8m) | $2.6m | $232k | $3.4m | $3.4m | |
| Pre-Tax Income | — | — | $7.9m | ($829k) | ($45.5m) | ($58.0m) | ($7.6m) | ($49.5m) | ($49.2m) | ($49.2m) | |
| Deferred Tax Expense (Income) | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Income Tax Expense Continuing Operations | $368k | ($333k) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income (loss) from continuing operations | — | — | $7.9m | ($829k) | ($45.5m) | ($58.0m) | ($7.6m) | ($49.5m) | ($49.2m) | ($49.2m) | |
| Net Income From Continuing And Discontinued Operation | ($48.4m) | $3.0m | ($20.8m) | ($64.0m) | ($52.8m) | ($58.1m) | ($7.6m) | ($49.5m) | ($49.2m) | ($49.2m) | |
| Net income (loss) before tax | ($48.0m) | $2.7m | ($20.8m) | ($64.0m) | ($45.5m) | ($58.0m) | ($7.6m) | ($49.5m) | ($49.2m) | ($49.2m) | |
| Net Income Discontinuous Operations | — | — | — | — | — | ($131k) | $0 | $0 | $0 | $0 | |
| Basic Earnings (Loss) Per Share | ($0.89) | $0.05 | ($0.31) | ($0.81) | ($0.66) | ($0.73) | ($0.09) | ($0.61) | ($0.55) | ($0.55) | |
| Diluted Earnings (Loss) Per Share | ($0.89) | $0.05 | ($0.31) | ($0.81) | ($0.66) | ($0.73) | ($0.09) | ($0.61) | ($0.55) | ($0.55) | |
| Basic income (loss) per share from continuing operations (in EUR per share) | — | — | $0.12 | ($0.01) | ($0.57) | ($0.73) | ($0.09) | ($0.61) | ($0.55) | — | |
| Diluted income (loss) per share from continuing operations (in EUR per share) | — | — | $0.12 | ($0.01) | ($0.57) | ($0.73) | ($0.09) | ($0.61) | ($0.55) | — | |
| Basic income (loss) per share from discontinued operations (in EUR per share) | — | — | ($0.43) | ($0.80) | ($0.09) | $0.00 | $0.00 | $0.00 | $0.00 | — | |
| Diluted income (loss) per share from discontinued operations (in EUR per share) | — | — | ($0.43) | ($0.80) | ($0.09) | $0.00 | $0.00 | $0.00 | $0.00 | — | |
| Basic Average Shares | — | — | — | — | — | $79.6m | $84.1m | $81.1m | $89.6m | $89.6m | |
| Diluted Average Shares | — | — | — | — | — | $79.6m | $84.1m | $81.1m | $89.6m | $89.6m | |
| Additional Financial Items | |||||||||||
| Applicable Tax Rate | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Average Effective Tax Rate | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Depreciation Property Plant And Equipment Including Right of Use Assets | — | — | — | — | — | — | — | $1.6m | $1.4m | — | |
| Finance Income | $2.5m | $6.0m | $11.3m | $4.9m | $6.3m | $4.8m | $6.9m | $6.1m | $8.0m | — | |
| Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill | — | — | — | $43.5m | — | $41.0m | $0 | $0 | $0 | — | |
| Profit Loss Before Tax | ($48.0m) | $2.7m | ($20.8m) | ($64.0m) | ($45.5m) | ($58.0m) | ($7.6m) | ($49.5m) | ($49.2m) | — | |
| Profit Loss From Operating Activities | — | $5.1m | ($27.1m) | ($62.1m) | ($47.8m) | ($57.4m) | ($12.7m) | ($51.6m) | ($54.0m) | — | |
| Government financing for research expenditures | $11.4m | $14.1m | $16.8m | $13.6m | $12.6m | $8.0m | $9.7m | $7.5m | $6.2m | — | |
| Impairment of intangible assets | — | $0 | $0 | ($43.5m) | $0 | ($41.0m) | $0 | $0 | $0 | — | |
| Financial income | $2.5m | $6.0m | $11.3m | $4.9m | $6.3m | $4.8m | $6.9m | $6.1m | $8.0m | — | |
| Net financial income (loss) | ($8.0m) | ($2.4m) | $6.3m | ($1.9m) | $2.3m | ($546k) | $5.1m | $2.1m | $4.8m | — | |
| Diluted EPS | ($0.89) | $0.05 | ($0.31) | ($0.81) | ($0.66) | ($0.73) | ($0.09) | ($0.61) | ($0.55) | ($0.55) | |
| Diluted NI Availto Com Stockholders | ($48.4m) | $3.0m | ($20.8m) | ($64.0m) | ($52.8m) | ($58.1m) | ($7.6m) | ($49.5m) | ($49.2m) | ($49.2m) | |
| Impairment Of Capital Assets | — | — | — | $43.5m | — | $41.0m | $0 | $0 | $0 | $0 | |
| Normalized EBITDA | — | — | — | — | — | $29.5m | ($8.1m) | ($47.1m) | ($47.0m) | ($43.6m) | |
| Normalized Income | — | — | — | — | — | ($16.2m) | ($10.1m) | ($49.7m) | ($52.5m) | ($52.5m) | |
| Other Gand A | — | — | — | — | — | $4.2m | $2.9m | $3.4m | $3.0m | — | |
| Reconciled Depreciation | — | — | — | — | — | $45.4m | $1.4m | $2.0m | $5.1m | $5.1m | |
| Salaries And Wages | — | — | — | — | — | $10.2m | $8.8m | $8.6m | $8.0m | $8.0m | |
| Selling General And Administration | — | — | — | — | — | $14.5m | $11.7m | $11.9m | $11.0m | — | |
| Special Income Charges | — | — | — | — | — | ($41.0m) | $0 | $0 | ($583k) | ($583k) | |
| Tax Effect Of Unusual Items | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Tax Provision | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Tax Rate For Calcs | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Depreciation And Amortisation Expense | — | $7.4m | $16.5m | $13.3m | $4.6m | $4.4m | $5.1m | $2.0m | $1.4m | — | |
| Employee Benefits Expense | — | $21.8m | $26.5m | $27.9m | $26.1m | $26.6m | $26.0m | $26.1m | $27.4m | — | |
| Expense From Share-Based Payment Transactions With Employees | — | $2.7m | $3.8m | $2.5m | $2.6m | $4.2m | $4.3m | $3.9m | $2.6m | — | |
| Finance Costs | — | $8.4m | $5.0m | $6.8m | $4.0m | $5.3m | $1.8m | $4.0m | $3.1m | — | |
| Postemployment Benefit Expense Defined Contribution Plans | — | $1.3m | $1.4m | $1.4m | $1.4m | $1.4m | $1.3m | $1.3m | $1.3m | — | |
| Financial expenses | ($10.5m) | ($8.4m) | ($5.0m) | ($6.8m) | ($4.0m) | ($5.3m) | ($1.8m) | ($4.0m) | ($3.1m) | — | |
| Operating Expense | — | — | — | — | — | $66.0m | $64.6m | $64.2m | $56.2m | $56.2m | |
| Net Foreign Exchange Loss | — | $3.9m | $4.8m | $5.6m | $3.6m | $3.0m | $1.2m | $3.4m | $2.7m | — | |
| Total Unusual Items | — | — | — | — | — | ($41.8m) | $2.6m | $232k | $3.4m | $3.4m | |
| Total Expenses | — | — | — | — | — | $66.0m | $64.6m | $64.2m | $56.2m | $56.2m |